2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Multiple Myeloma
121
Neoplasms, Plasma Cell
36
Neoplasms
14
Carcinoma, Hepatocellular
13
Recurrence
12
Brain Neoplasms
12
Prostatic Neoplasms
11
Melanoma
11
Central Nervous System Neoplasms
11
Glioblastoma
10
Leukemia
9
Carcinoma, Non-Small-Cell Lung
9
Leukemia, Lymphocytic, Chronic, B-Cell
8
Gliosarcoma
8
Waldenstrom Macroglobulinemia
7
Sarcoma
7
Lung Neoplasms
7
Glioma
7
Colorectal Neoplasms
7
Carcinoma, Renal Cell
7
Liver Neoplasms
6
Myeloproliferative Disorders
5
Myelodysplastic Syndromes
5
Lymphoma, Mantle-Cell
5
Lymphoma, B-Cell, Marginal Zone
5
Lymphoma
5
Kidney Neoplasms
5
Immunoglobulin Light-chain Amyloidosis
5
Myelodysplastic-Myeloproliferative Diseases
4
Lymphoma, Follicular
4
Interventions
Dexamethasone
38
Aprepitant
31
Ondansetron
27
Palonosetron
25
Granisetron
16
Calcium Dobesilate
15
Olanzapine
13
Therapeutics
8
dexamethasone acetate
7
Cyclophosphamide
7
fosaprepitant
6
casopitant
6
Doxorubicin
6
Radiotherapy
5
netupitant
4
dolasetron
4
dexamethasone 21-phosphate
4
Vincristine
4
Tropisetron
4
Metoclopramide
4
Acupressure
4
Yoga
3
Surveys and Questionnaires
3
Psychiatric Rehabilitation
3
Prochlorperazine
3
Lorazepam
3
Electroacupuncture
3
Dronabinol
3
Cisplatin
3
Analgesia
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Nausea
×
Thalidomide
×
Clear all
NCT06017284
2023-11-24
PTCA199-5
Fudan University
Phase 3
Recruiting
100 enrolled